Last updated: September 29, 2026
Ryzolt was a once-daily extended-release tramadol hydrochloride tablet marketed by Purdue Pharma. The product entered a mature analgesic market dominated by generic immediate-release tramadol and competing extended-release products. Its commercial opportunity was constrained by generic substitution, limited differentiation from other tramadol formulations, opioid-class regulatory pressure, and Purdue’s withdrawal of the product from the U.S. market. Ryzolt does not have a meaningful current revenue base, and public filings do not report standalone product sales.
What was Ryzolt and who marketed it?
Ryzolt contained tramadol hydrochloride in extended-release tablet strengths of 100 mg, 200 mg, and 300 mg. The product was designed for once-daily treatment of chronic pain in adults requiring around-the-clock opioid analgesia.
| Item |
Ryzolt |
| Active ingredient |
Tramadol hydrochloride |
| Dosage form |
Extended-release oral tablet |
| Strengths |
100 mg, 200 mg, 300 mg |
| Sponsor |
Purdue Pharma L.P. |
| FDA application |
NDA 022370 |
| Therapeutic category |
Opioid analgesic |
| Initial U.S. approval |
2008 |
| Commercial status |
Discontinued in the U.S. |
| Current branded revenue |
No separately reported material revenue |
The product competed with Ultram ER, generic extended-release tramadol, immediate-release tramadol, and other chronic-pain therapies. Tramadol’s lower historical abuse perception relative to stronger Schedule II opioids supported earlier adoption, but the product remained subject to opioid safety, dependence, misuse, and respiratory-depression concerns.
When did Ryzolt lose exclusivity?
Ryzolt’s commercial exclusivity eroded after approval because the active ingredient, tramadol, was already widely available in generic immediate-release form. The product’s protection depended primarily on formulation patents and regulatory exclusivity rather than compound exclusivity.
The principal U.S. patent associated with the extended-release tramadol formulation was U.S. Patent No. 6,254,887. The patent covered sustained-release tramadol formulations and was listed in connection with extended-release tramadol products. Its nominal expiration was in 2019, subject to any applicable patent-term adjustment or extension.
Ryzolt exclusivity timeline
| Date or period |
Event |
| 1990s |
Immediate-release tramadol gains broad U.S. market access |
| 2008 |
FDA approves Ryzolt under NDA 022370 |
| 2008-2010 |
Branded launch and early commercial positioning |
| 2010s |
Generic tramadol ER competition develops |
| 2014 |
Tramadol is placed into Schedule IV under the federal Controlled Substances Act |
| 2019 |
Principal formulation-patent term reaches its nominal endpoint |
| Current status |
Ryzolt is not an active commercial growth product |
The practical loss of exclusivity occurred before the core patent expiration because generic competitors could challenge listed patents, pursue abbreviated new drug applications, and compete against a product with limited brand differentiation.
What is the FDA regulatory status of Ryzolt?
Ryzolt was approved by the FDA for the management of pain severe enough to require an opioid analgesic and for which alternative treatments were inadequate. The product’s approval was based on its extended-release delivery profile rather than a new active pharmaceutical ingredient.
The product was later withdrawn from commercial distribution. FDA’s “Discontinued Drug Product List” is the relevant regulatory source for determining whether a product was withdrawn for commercial reasons or for safety or efficacy concerns. A product listed as discontinued for commercial reasons generally does not imply that FDA determined the drug was unsafe or ineffective.
Ryzolt’s regulatory position was weakened by the 2014 federal scheduling of tramadol as a Schedule IV controlled substance. That change increased prescribing, dispensing, inventory, recordkeeping, and compliance burdens across the tramadol market.
What patents protected Ryzolt?
Formulation patents
The key protection for Ryzolt was its extended-release formulation. The commercial value of a formulation patent depends on whether the claims cover the specific release mechanism, dosage form, excipients, manufacturing process, or dose range used by a generic competitor.
U.S. Patent No. 6,254,887 is the principal patent associated with sustained-release tramadol formulations. The patent’s relevant commercial function was to protect once-daily delivery rather than the tramadol molecule itself.
The patent estate was relatively narrow compared with the estates of newer specialty medicines. Tramadol was a long-established active ingredient, and the product did not have substantial biologic, device, or complex-manufacturing barriers.
Method-of-use patents
Ryzolt’s value was not based on a broad new method of treatment. Its labeling covered chronic pain requiring around-the-clock opioid therapy. Method-of-use claims in this setting face practical enforcement limits because generic labels may omit patented indications while physicians can prescribe the product off-label.
Manufacturing and process protection
The product’s manufacturing protection was less commercially important than the oral formulation claims. Generic manufacturers could generally source tramadol hydrochloride from established suppliers and use conventional tablet manufacturing infrastructure, subject to demonstrating bioequivalence and extended-release performance.
How many patents covered Ryzolt?
Ryzolt did not have the type of extensive multi-layer patent estate associated with newer branded drugs. Its protection was concentrated in a small number of formulation-related patents, with U.S. Patent No. 6,254,887 the most prominent publicly associated patent.
The commercial barrier was therefore limited to:
- Extended-release formulation design.
- Bioequivalence testing.
- FDA approval of the generic product.
- Controlled-substance manufacturing and distribution compliance.
This structure made Ryzolt more vulnerable to generic erosion than products protected by composition-of-matter, formulation, delivery-device, metabolite, method-of-use, and manufacturing patents operating together.
Which companies challenged or competed with Ryzolt?
Ryzolt competed against several categories of products rather than a single direct rival.
| Competitive category |
Examples |
Market effect |
| Generic immediate-release tramadol |
Multiple U.S. generic manufacturers |
Low-cost substitution and broad prescriber familiarity |
| Generic extended-release tramadol |
Authorized and abbreviated-application competitors |
Direct erosion of Ryzolt’s once-daily franchise |
| Ultram ER |
Original branded extended-release tramadol |
Direct branded competition |
| Other opioid analgesics |
Hydrocodone, oxycodone, morphine, tapentadol |
Alternative treatment choices |
| Non-opioid therapies |
NSAIDs, acetaminophen, anticonvulsants, antidepressants |
Reduced addressable opioid demand |
| Abuse-deterrent opioids |
Selected extended-release opioid products |
Competing positioning for chronic pain |
Publicly visible commercial pressure came primarily from generic substitution and the expanding use of non-opioid pain therapies, not from a single high-profile patent litigation campaign.
What was the Paragraph IV risk for Ryzolt?
The principal Paragraph IV risk involved generic extended-release tramadol applicants asserting that listed formulation patents were invalid, unenforceable, or not infringed. A Paragraph IV certification can trigger patent litigation under the Hatch-Waxman Act and may create a 30-month stay of FDA approval if the branded sponsor files suit within the statutory period.
Ryzolt’s Paragraph IV exposure was structurally high because:
- The active ingredient was off patent.
- The formulation was an oral tablet rather than a complex delivery system.
- Generic tramadol manufacturers had established API access.
- Once-daily tramadol had clear therapeutic and commercial demand.
- The brand had limited ability to sustain premium pricing after generic entry.
No major, enduring Ryzolt litigation campaign is generally identified as a continuing market constraint. The product’s withdrawal reduced the economic value of pursuing prolonged enforcement.
Did Ryzolt have biosimilar risk?
No. Ryzolt was a small-molecule oral drug, not a biologic. Biosimilar legislation and biologic reference-product exclusivity did not apply.
Ryzolt faced generic-drug risk under the ANDA pathway. The relevant regulatory issues were bioequivalence, extended-release performance, formulation similarity, labeling, and controlled-substance compliance.
What was Ryzolt’s financial trajectory?
Ryzolt’s financial trajectory was likely short-lived and modest relative to major opioid brands. Purdue Pharma was privately held, and public reporting did not disclose a standalone Ryzolt revenue series. Available public materials do not support a reliable product-level estimate for peak sales, cumulative revenue, gross margin, or contribution to Purdue’s opioid portfolio.
Commercial trajectory
| Phase |
Market condition |
Financial implication |
| Launch |
New once-daily tramadol formulation |
Opportunity for modest premium pricing |
| Early commercialization |
Established generic tramadol market |
Limited ability to build a large franchise |
| Generic pressure |
Extended-release alternatives emerge |
Rapid price and volume erosion |
| Regulatory tightening |
Tramadol becomes Schedule IV |
Higher compliance cost and prescribing friction |
| Withdrawal |
Product leaves commercial market |
Revenue falls to immaterial or zero levels |
Ryzolt lacked several attributes associated with large pharmaceutical cash flows:
- It had no new molecular entity exclusivity.
- It treated a crowded and price-sensitive category.
- Immediate-release generic tramadol was already familiar to prescribers.
- The once-daily benefit was incremental rather than transformational.
- Opioid prescribing declined under tighter regulatory and payer controls.
- Purdue’s corporate focus shifted toward opioid litigation, restructuring, and newer opioid products.
What caused Ryzolt’s commercial decline?
Generic substitution
Generic tramadol reduced the price ceiling for all branded tramadol products. Extended-release branding could support some premium, but the clinical distinction was not large enough to prevent substitution across many payer and prescribing environments.
Limited product differentiation
Ryzolt offered once-daily dosing, but competing analgesics also offered extended-release or long-acting administration. The product therefore competed on convenience in a market where price, formulary status, and opioid-risk management carried greater weight.
Controlled-substance regulation
Tramadol became federally scheduled in 2014. Prescribers and pharmacies faced additional compliance requirements, while health systems increased opioid stewardship controls. These measures reduced the attractiveness of chronic opioid therapy.
Opioid-market contraction
The U.S. opioid market faced prescribing restrictions, litigation, payer scrutiny, prescription-monitoring requirements, and shifts toward non-opioid treatment. Those forces affected both branded and generic tramadol.
Purdue’s corporate restructuring
Purdue’s financial distress and bankruptcy restructuring reduced the likelihood of sustained investment in lower-growth products. A discontinued product with limited standalone sales would have had low strategic priority compared with assets central to Purdue’s restructuring and litigation profile.
What is the Orange Book status of Ryzolt?
Ryzolt’s Orange Book relevance is historical rather than commercial. FDA Orange Book records may identify the product’s approval, dosage forms, patent listings, and marketing status. The product’s discontinued status means it should not be treated as an active branded competitor in current U.S. market forecasts.
Orange Book analysis should distinguish among:
- Drug approval status.
- Patent-listing status.
- Marketing status.
- Withdrawal reason.
- Availability of therapeutically equivalent generic products.
A discontinued brand can remain relevant to patent history without representing current revenue or market share.
How strong was the Ryzolt patent estate?
Ryzolt had a weak-to-moderate patent estate from a commercial protection perspective.
| Factor |
Assessment |
| Active ingredient protection |
Weak; tramadol was established and generic |
| Formulation protection |
Moderate during the effective patent term |
| Method-of-use protection |
Limited practical leverage |
| Manufacturing barriers |
Low to moderate |
| Regulatory exclusivity |
Limited |
| Biosimilar protection |
Not applicable |
| Litigation leverage |
Limited after generic competition |
| Long-term revenue durability |
Low |
The estate could delay or complicate generic entry, but it could not support long-duration exclusivity comparable to a patented new chemical entity.
What generic launch scenarios existed for Ryzolt?
The likely generic-entry scenarios were:
- Early negotiated entry: A generic manufacturer launches before full patent expiration under a settlement or license.
- Post-expiration launch: Generic approval follows patent expiry without an effective enforceable barrier.
- At-risk launch: A generic enters after losing or avoiding an injunction, exposing itself to damages if the patent is later upheld.
- Market substitution after withdrawal: Generic extended-release tramadol supplies the remaining once-daily demand after the branded product exits.
The most commercially important outcome was not a single launch date. It was the replacement of Ryzolt by lower-priced generic tramadol products within a mature analgesic market.
How does Ryzolt compare with other branded opioid products?
| Attribute |
Ryzolt |
Stronger branded opioid franchise |
| New active ingredient |
No |
Often yes |
| Composition-of-matter patent |
No meaningful remaining protection |
Common |
| Differentiation |
Once-daily tramadol dosing |
May include abuse deterrence or novel delivery |
| Generic vulnerability |
High |
Variable |
| Prescriber switching cost |
Low |
Higher where clinical differentiation exists |
| Pricing power |
Limited |
Higher for differentiated products |
| Regulatory exposure |
High |
High |
| Current revenue potential |
Minimal |
Depends on active exclusivity |
Ryzolt’s market position was closer to a reformulated legacy drug than to a durable specialty pharmaceutical franchise.
Key Takeaways
- Ryzolt was Purdue Pharma’s once-daily extended-release tramadol product, approved in the U.S. in 2008.
- Its commercial protection centered on formulation patents, particularly U.S. Patent No. 6,254,887, rather than active-ingredient exclusivity.
- The product faced immediate structural pressure from generic immediate-release tramadol and later generic extended-release competition.
- Tramadol’s 2014 classification as a Schedule IV controlled substance increased compliance burdens and contributed to a more restrictive market.
- Ryzolt was discontinued and has no publicly reported material current revenue.
- The product had no biosimilar risk because tramadol is a small-molecule drug.
- Its patent estate was limited and unlikely to support long-term pricing power.
- Ryzolt’s financial trajectory was launch, limited branded growth, generic erosion, and commercial withdrawal.
FAQs About Ryzolt Market and Patent Risk
Is Ryzolt still available in the United States?
No. Ryzolt is a discontinued U.S. extended-release tramadol brand. Generic tramadol products remain available subject to FDA approval and controlled-substance requirements.
Did Ryzolt have a composition-of-matter patent?
No meaningful composition-of-matter protection applied to Ryzolt’s commercial position. The active ingredient, tramadol, was already established. Protection focused on extended-release formulation technology.
Was Ryzolt an opioid?
Yes. Ryzolt contained tramadol, an opioid analgesic with additional monoaminergic pharmacology. Tramadol is federally classified as a Schedule IV controlled substance in the United States.
Could a generic company launch Ryzolt without infringing its patents?
A generic applicant would need to address listed patents through the ANDA certification process. Launch timing would depend on patent validity, infringement findings, settlement terms, FDA approval, and any applicable exclusivity or litigation stay.
Did Purdue disclose Ryzolt sales separately?
No reliable standalone Ryzolt revenue series is generally available in Purdue’s public financial materials. Purdue’s reporting did not provide a sustained product-level sales history sufficient to calculate Ryzolt’s peak revenue or cumulative lifetime sales.
References
-
U.S. Food and Drug Administration. (2008). Ryzolt prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (n.d.). Discontinued drug product list. FDA.
-
U.S. Patent and Trademark Office. (2001). U.S. Patent No. 6,254,887: Sustained release formulation for tramadol. USPTO.
-
Drug Enforcement Administration. (2014). Placement of tramadol into schedule IV. 79 Fed. Reg. 37623.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.
